DOI: 10.1128/AAC.02102-19
Article Information
PubMed
Published By
History
- Received October 17, 2019
- Returned for modification November 10, 2019
- Accepted November 14, 2019
- Published online January 27, 2020.
Copyright & Usage
Copyright © 2020 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (November 25, 2019).
- You are viewing the most recent version of this article.
Author Information
- E. Wenzlera,
- K. M. Meyera,
- S. C. Bleasdaleb,
- M. Sikkab*,
- R. E. Mendesc,
- K. L. Bunnella*,
- M. Finnemeyerd,
- S. L. Rosenkranzd,
- L. H. Danzigera,b and
- K. A. Rodvolda,b
- for the Antibacterial Resistance Leadership Group
- aCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
- bCollege of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
- cJMI Laboratories, North Liberty, Iowa, USA
- dHarvard TH Chan School of Public Health, Boston, Massachusetts, USA
- Address correspondence to K. A. Rodvold, kar{at}uic.edu.
↵* Present address: M. Sikka, Oregon Health & Science University, Portland, Oregon, USA; K. L. Bunnell, Medical College of Wisconsin School of Pharmacy, Milwaukee, Wisconsin, USA.
Citation Wenzler E, Meyer KM, Bleasdale SC, Sikka M, Mendes RE, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA, for the Antibacterial Resistance Leadership Group. 2020. Ex vivo urinary bactericidal activity and urinary pharmacodynamics of fosfomycin after two repeated dosing regimens of oral fosfomycin tromethamine in healthy adult subjects. Antimicrob Agents Chemother 64:e02102-19. https://doi.org/10.1128/AAC.02102-19.
